The FDA last week approved AcelRx‘s (NSDQ:ACRX) Dsuvia sufentanil product, noting that use of the opioid will be tightly restricted to adults experiencing acute pain in medically-supervised healthcare settings.
Dsuvia is a tablet that is administered sublingually in a single-dose, pre-filled applicator. The company expects to launch its pain product in the first quarter of 2019.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA to develop new framework for opioid analgesics following AcelRx approval appeared first on MassDevice.
from MassDevice https://ift.tt/2qvrbqa
Cap comentari:
Publica un comentari a l'entrada